181 related articles for article (PubMed ID: 35124386)
1. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020.
Behrends CN; Lu X; Corry GJ; LaKosky P; Prohaska SM; Glick SN; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC
Drug Alcohol Depend; 2022 Mar; 232():109323. PubMed ID: 35124386
[TBL] [Abstract][Full Text] [Related]
2. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.
Frost MC; Sweek EW; Austin EJ; Corcorran MA; Juarez AM; Frank ND; Prohaska SM; LaKosky PA; Asher AK; Broz D; Jarlais DCD; Williams EC; Glick SN
AIDS Behav; 2022 Jan; 26(1):57-68. PubMed ID: 34110506
[TBL] [Abstract][Full Text] [Related]
3. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.
Austin EJ; Corcorran MA; Briggs ES; Frost MC; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Jarlais DCD; Williams EC; Glick SN
Int J Drug Policy; 2022 Nov; 109():103825. PubMed ID: 35977459
[TBL] [Abstract][Full Text] [Related]
4. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
6. Availability of and Obstacles to Providing COVID-19 Vaccinations at Syringe Services Programs in the United States, 2021.
Des Jarlais DC; Behrends CN; Corcorran MA; Glick SN; Perlman DC; Kapadia SN; Lu X; Feelemyer J; LaKosky P; Prohaska SM; Schackman BR
Public Health Rep; 2022; 137(6):1066-1069. PubMed ID: 36113105
[TBL] [Abstract][Full Text] [Related]
7. Access to HIV, Viral Hepatitis, and Substance Use Disorder Treatment/Overdose Prevention Services: A Qualitative Analysis of Syringe Service Programs (SSPs) Serving Rural PWID.
Carnes NA; Asher AK; Bohm MK; Bessler PA
Subst Use Misuse; 2021; 56(13):1933-1940. PubMed ID: 34353216
[TBL] [Abstract][Full Text] [Related]
8. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.
Krawczyk N; Allen ST; Schneider KE; Solomon K; Shah H; Morris M; Harris SJ; Sherman SG; Saloner B
Harm Reduct J; 2022 Aug; 19(1):95. PubMed ID: 36002850
[TBL] [Abstract][Full Text] [Related]
9. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
[TBL] [Abstract][Full Text] [Related]
10. State Laws Governing Syringe Services Programs and Participant Syringe Possession, 2014-2019.
Fernández-Viña MH; Prood NE; Herpolsheimer A; Waimberg J; Burris S
Public Health Rep; 2020; 135(1_suppl):128S-137S. PubMed ID: 32735195
[TBL] [Abstract][Full Text] [Related]
11. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
[TBL] [Abstract][Full Text] [Related]
12. Vaccination barriers and opportunities at syringe services programs in the United States, June-August 2021-A cross-sectional survey.
Montgomery MP; Zhong Y; Roberts E; Asher A; Bixler D; Doshani M; Christensen A; Eckert M; Weng MK; Carry M; Samuel CR; Teshale EH
Drug Alcohol Depend; 2022 Aug; 237():109540. PubMed ID: 35753280
[TBL] [Abstract][Full Text] [Related]
13. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
[TBL] [Abstract][Full Text] [Related]
14. Application of machine learning algorithms for localized syringe services program policy implementation - Florida, 2017.
Bartholomew TS; Tookes HE; Spencer EC; Feaster DJ
Ann Med; 2022 Dec; 54(1):2137-2150. PubMed ID: 35900201
[TBL] [Abstract][Full Text] [Related]
15. Police officer attitudes towards syringe services programming.
Sightes E; Ray B; Paquet SR; Bailey K; Huynh P; Weintraut M
Drug Alcohol Depend; 2019 Dec; 205():107617. PubMed ID: 31707271
[TBL] [Abstract][Full Text] [Related]
16. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019.
Lambdin BH; Bluthenthal RN; Wenger LD; Wheeler E; Garner B; Lakosky P; Kral AH
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1117-1121. PubMed ID: 32817603
[TBL] [Abstract][Full Text] [Related]
17. Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises.
Wenger LD; Kral AH; Bluthenthal RN; Morris T; Ongais L; Lambdin BH
Transl Res; 2021 Aug; 234():159-173. PubMed ID: 33746108
[TBL] [Abstract][Full Text] [Related]
18. Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them.
Broz D; Carnes N; Chapin-Bardales J; Des Jarlais DC; Handanagic S; Jones CM; McClung RP; Asher AK
Am J Prev Med; 2021 Nov; 61(5 Suppl 1):S118-S129. PubMed ID: 34686281
[TBL] [Abstract][Full Text] [Related]
19. Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency.
Bartholomew TS; Tookes HE; Chueng TA; Bluthenthal RN; Wenger LD; Kral AH; Lambdin BH
Harm Reduct J; 2023 Sep; 20(1):122. PubMed ID: 37660029
[TBL] [Abstract][Full Text] [Related]
20. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic.
Lindqvist K; Wallmofeldt C; Holmén E; Hammarberg A; Kåberg M
Harm Reduct J; 2021 May; 18(1):52. PubMed ID: 33971892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
